fbpx
Connect with us
  • Elysium

Stroke news

Pioneering stroke treatment company Aurum Biosciences appoint new CEO

Published

on

Stroke tech company Aurum Biosciences have appointed a new CEO as they continue to work on what is being touted as the first major advancement in stroke treatment in two decades.

The move to appoint a new CEO comes as they aim to expand its global presence and as the company continues to work on its patented ABL-101 platform, which is a therapeutic drug based on a small molecule that can carry oxygen past a blood clot to where it is needed in the brain.

“Aurum is also developing this technology in other clinical indications such as inflammatory conditions, oncology, cardiovascular conditions, spinal cord injury and dementia.”

Preclinical development has been completed and Aurum has been granted approval to initiate clinical studies in acute stroke patients. 

David Brennan (Image credit: The Herald)

David Brennan will take over the leaving Jim McGuire’s duties as the head of the Glasgow based company. Brennan has already served as interim chief executive of Aurum and also worked at the nearby Queen Elizabeth University Hospital as their principal clinical physicist.

Brennan says he is “incredibly proud to have taken up this exciting role” as well as fully committing his future to Aurum.

Brennan continues to say: “I was a founding member of the company and previously director of project management, taking a keen interest in all aspects of company development, but when the opportunity to become CEO arose, I simply couldn’t turn it down.

“Aurum has grown so much since I first came onboard. Initially, I thought we would just licence out the technology, then it became a spinout with a whole new life of its own and a very bright future.”

Established in 2015 as a spin-out from InnoScot Health, NHS Greater Glasgow and Clyde, and the University of Glasgow. In 2020 the company raised £670,000 as part of a round of equity funding, which would allow them to develop its treatments and diagnostics that have attracted international investment and collaborations.

HIWIN

Trending